Objective: Evaluation of thyroid hormone response to a single administration of triiodothyronine (T 3 ) early postnatally to premature infants of ,30 weeks gestational age. Design: A prospective clinical trial with historical control. Methods: Ten infants born ,28 weeks gestational age and ten infants born between 28 and 30 weeks gestational age were given 0.5 mg/kg T 3 intravenously at 12 h after birth. The infants ,28 weeks gestational age were also treated with thyroxine (T 4 ; 8 mg/kg, once daily) during the first 6 weeks of life. Premature infants from a previous trial served as a matched historical control group. Analysis of variance for repeated measurements was performed. Results: For the infants 28±30 weeks gestational age mean plasma T 3 concentrations were significantly higher in the T 3 -treated group P 0X027 for at least 2 weeks, whereas mean plasma levels of T 4 , free T 4 and TSH were comparable. For the infants ,28 weeks gestational age plasma T 3 levels were also significantly different after correction for gestational age P 0X0002Y with either comparable or higher values in the T 3 -treated infants up to 56 days after injection of T 3 . Mean plasma free T 4 levels were lower during the first 3 days and higher or comparable thereafter P 0X0014Y and TSH suppression was more evident in the T 3 -treated infants P 0X003X Conclusion: A single administration of T 3 to premature infants ,30 weeks gestational age early postnatally results in a sustained increase of plasma T 3 levels during the first weeks of life. In infants of 28±30 weeks gestational age this occurs without change in plasma free T 4 levels, whereas in infants ,28 weeks gestational age a transient decrease of plasma free T 4 was present. The increase in plasma T 3 is possibly caused by a T 3 -induced increase of type I deiodinase activity.
Introduction
Transient hypothyroxinemia is a common finding in the first weeks of life in premature infants (1±3). It is characterised by low levels of thyroxine (T 4 ) and triiodothyronine (T 3 ), in the presence of normal levels of thyrotropin (TSH). The degree of hypothyroxinemia depends on the gestational age (GA) and the severity of disease, resulting in lower T 4 levels in the younger and the more severely ill infants (2) . It is believed to be caused, at least in part, by immaturity of the hypothalamic±pituitary±thyroid axis and by the abrupt discontinuation of transplacentally transferred maternal T 4 (4) . The significance of the hypothyroxinemia remains unclear, and whether it is appropriate to treat or not to treat, is still a subject of debate (5) . However, both low T 4 and low T 3 levels in premature infants have been associated with poor neurological and developmental outcome in several studies (6±12). A recent randomized controlled trial of T 4 supplementation in premature infants in our institution and one from a Belgian group failed to show any improvement in neurodevelopmental outcome (13, 14) . However, in our trial T 4 supplementation seemed to be associated with an improvement in mental developmental outcome in the subgroup of infants of less than 27 weeks gestation (13) . Besides increasing plasma T 4 and free T 4 levels, T 4 supplementation resulted in a suppression of TSH levels, whereas plasma T 3 levels did not increase (15) , but, on the contrary, decreased (16) . It is believed that the low plasma T 3 level in premature infants is related to low activity of the type I deiodinase (DI), which is responsible for the endogenous production of T 3 by an outer ring deiodination of T 4 to T 3 (17) . Another explanation for the low T 3 levels, however, could be a higher elimination rate of T 3 by the type III deiodinase (DIII), which is abundantly present in fetal tissues (18±20) and is responsible for the deiodination of T 3 to diiodothyronine. As a result, T 3 concentrations remain low in preterm infants early in life. Moreover, sulfation of iodothyronines remains active in very preterm infants, as during the fetal period (21, 22) . These sulfoconjugates are metabolized by DI and as a consequence of the low DI activity high circulating levels can be found in fetal/preterm life. It has been suggested that sulfated T 3 could serve as a local source of T 3 in fetal tissues containing sulfatase.
There is evidence that DI is responsive to T 3 itself. Higher T 3 concentrations enhance deiodinase activity (23) . Thus, administration of T 3 could result in a sustained increase of plasma T 3 as a result of higher DI levels and thereby increased endogenous conversion of T 4 to T 3 .
Because in our former trial T 4 supplementation was not beneficial in infants between 28 and 30 weeks GA, but seemed to improve neurodevelopmental outcome in infants ,28 weeks GA (24) , two groups were present in this study. The aim of the study was to investigate whether a single administration of T 3 given to premature infants ,30 weeks GA shortly after birth, could result in a sustained increase of plasma T 3 concentrations. Infants 28±30 weeks GA were given only T 3 . Infants ,28 weeks GA were given T 3 , and subsequently received T 4 during the first weeks of life according our former protocol (13) .
Our results indicate that a single T 3 dose shortly after birth indeed results in a sustained increase in plasma levels of T 3 .
Subjects and methods

Study population
Infants admitted to the Neonatal Intensive Care Unit of the Academic Medical Centre in Amsterdam (The Netherlands) who were born between April and October 1998 with a GA ,30 weeks were eligible for the study. Infants were excluded if they had a severe congenital anomaly. Ten infants born ,28 weeks GA, and ten infants born at 28 weeks or later, but before the 30th week of gestation were recruited. If informed consent had been obtained from at least one of the parents within 12 h of birth, the infant was included in the study.
This study was approved by the Committee of Medical Ethics of the Academic Medical Centre in Amsterdam.
Intervention
Infants 28±30 weeks GA The infants born between 28 and 30 weeks GA received a single dose of T 3 (Liothyronine, 2.5 mg/ml; manufactured by the hospital pharmacy) of 0.5 mg/kg birthweight, administered as a bolus intravenously at 12 h after birth (range 10± 14 h). They were not treated with T 4 , unless the plasma free T 4 level dropped below 10 pmol/l, our lower limit of the reference group (unpublished), during the first 3 weeks of life. If T 4 treatment appeared to be necessary, it was to be continued until the postnatal age of 42 days.
Infants ,28 GA The study infants born before the 28th week of gestation received a single intravenous dose of T 3 (0.5 mg/kg birthweight) at 12 h after birth (range 10±14 h). In addition, they received T 4 (Levothyroxine, 25 mg/ml; manufactured by the hospital pharmacy) at a dose of 8 mg/kg birthweight once daily during the first 6 weeks of life, starting 24 h after birth. T 4 was given intravenously until the infant was on full enteral feeding, and orally thereafter.
Assays
Whenever available, cord blood was obtained. A 0.5 ml blood sample was drawn 2 and 6 h after the administration of T 3 for the measurement of T 3 . Blood samples (1 ml) were taken at 24 h and again on day 3, day 7, day 14 and day 21. When the infant was on T 4 treatment, a blood sample was also obtained at day 42 and day 56. In all specimens T 4 , free T 4 , T 3 , reverse T 3 , TSH and thyroxine binding globulin (TBG) were determined. The assays used have been described previously (15) .
Blood pressure was measured either with an indwelling arterial catheter or using a non-invasive oscillometric pressure monitor (Dinamap, Critikon, The Netherlands). Blood pressure and heart rate were noted at hourly intervals and values were retrieved retrospectively from the patient's charts.
Historical control group
As controls, study patients from the previous trial with T 4 were used (13) . In this trial, which occurred at the same Neonatal Intensive Care Unit between January 1991 and July 1993, 200 infants of ,30 weeks GA were randomized to treatment with T 4 (8 mg/kg once daily during the first 6 weeks of life) or placebo. For the infants in the present study born ,28 weeks GA, infants from the treatment group of the T 4 trial were taken as controls, whereas for the infants between 28 and 30 weeks GA, infants from the placebo group were taken as controls. Control infants were matched for gestational age group and for antenatal treatment with corticosteroids.
Statistics
Data of heart rate and blood pressure were analysed using the paired t-test. Differences in the time course of hormone levels between treatment and control group were tested using analysis of variance for repeated measurements (BMDP 5V), in which hormone levels were analysed as a function of time, T 3 administration, gestational age and an interaction term between T 3 administration and time. A significant interaction term was also considered as an effect of treatment. Statistical significance was set at a P value of 0.05.
Results
The clinical characteristics of the study patients and the historical control group prior to and following the intervention are shown in Table 1 . For the group of infants $28 weeks GA, mean GA was slightly higher (29.4 versus 28.9 weeks, P 0X02Y and they received parenteral nutrition for a little longer. For the group of infants ,28 weeks GA, the mean gestational age was lower in the treatment group compared with the control group (26.3 versus 27.0 weeks, P 0X01X They were also intubated more frequently at birth P 0X03Y were ventilated for a longer period of time (17.7 versus 6.6 days, P 0X16 and received more parenteral nutrition (23.7 versus 17.0 days, P 0X03X Although these differences could be explained by the lower mean GA alone, changes in treatment policies in our unit could also be partially responsible.
Infants 28±30 weeks GA
In Fig. 1 the time course of mean plasma concentrations of T 3 , T 4 , free T 4 and TSH for the infants born between 28 and 30 weeks GA is shown. The plasma concentration of T 3 , measured 2 h after the administration, was 2.33 nmol/l, decreasing to 1.83 nmol/l and then further to 1.57 nmol/l at 6 and 12 h after T 3 administration respectively. Plasma T 3 levels were constantly and significantly higher in the T 3 -treated infants compared with control infants P 0X027X Plasma T 4 and free T 4 levels were not significantly different. It is clear that a single dose of T 3 to infants between 28 and 30 weeks GA does not lead to TSH suppression. Thus, a single T 3 administration resulted in higher plasma T 3 levels, without changing the concentrations of T 4 , free T 4 and TSH. Also, reverse T 3 and TBG levels were comparable between the two groups (data not shown). As none of the infants $28 weeks GA needed treatment with T 4 , data beyond 21 days of life were not available in this gestational age group.
Infants ,28 weeks GA Figure 2 shows the time course of the mean plasma concentrations of T 3 , T 4 , free T 4 and TSH for the infants ,28 weeks GA. The mean plasma levels of T 3 was 2.65 nmol/l 2 h after the administration, decreasing to 1.61 nmol/l and 1.31 nmol/l at 6 and 12 h after injection respectively. As the mean GA in the T 3 group is lower than in the control group, constantly lower plasma T 3 levels in the T 3 -treated infants were to be expected. However, plasma T 3 levels were either comparable or higher in this group. Indeed, the two curves were significantly different after correction for gestational age P 0X0002 for the effect of T 3 and P 0X0001Y interaction term). At day 56 the difference between the T 3 treated group and the control group was 1.0 nmol/l (2.8 versus 1.8 nmol/l). The time course of T 4 was significantly different between Table 1 The clinical characteristics of the study patients and the historical control group prior to and following the intervention. the two groups P 0X021Y interaction term) with somewhat lower T 4 levels in the T 3 group. Plasma levels of free T 4 were lower during the first 3 days and higher or comparable thereafter in the T 3 group. The free T 4 time course was again significantly different between both groups P 0X0014Y interaction term). The TSH suppression was more evident in the T 3 group P 0X003Y interaction term), but both groups showed an adequate TSH increase of approximately 2.5-fold in response to withdrawal of T 4 supplementation. There were no differences in plasma reverse T 3 levels and TBG levels between T 3 -treated and control infants (data not shown).
While maximum T 3 levels were measured 14±16 h after birth, no clinically significant changes in heart rate and blood pressure were seen in either gestational age group during the first 72 h of life.
Discussion
We hypothesized that in premature infants born ,30 weeks GA, who commonly have a transient hypothyroxinemia, a single administration of a relatively high dose of T 3 early postnatally, could result in an appropriate provision of T 3 to all tissues that need T 3 in the transition from intrauterine to extrauterine life. By intravenous injection of T 3 , the increase in plasma level will depend on the T 3 distribution volume and the half life of plasma T 3 . On administering 0.5 mg/kg T 3 (or 770 pmol/kg, molecular weight being 650), about 2.5±3.0 pmol/ml plasma was present after 2 h, indicating a large distribution volume. This is in accordance with the distribution volume for T 3 described in adults (25) . Moreover, the rapid decline of T 3 after injection indicates a short half life time of plasma T 3 . In this respect it is remarkable that in T 3 -treated infants plasma T 3 levels remain significantly higher during the first weeks of life compared with control infants, giving the impression of an increased T 3 production compared with control infants.
Thus, our results suggest that a single T 3 administration to premature infants ,30 weeks GA causes a sustained increase in plasma T 3 levels during the first weeks of life. For infants between 28 and 30 weeks GA, this increase of T 3 occurred without any effect on plasma T 4 and free T 4 levels. For infants ,28 weeks GA, however, both T 4 and free T 4 decreased transiently, and TSH was somewhat more suppressed. This could be the result of the T 3 injection or the small differences in gestational age and severity of disease between the treatment and control group.
In term newborn infants a T 3 rise normally occurs during the first day of life, which is believed to be caused mainly by enhanced thyroidal excretion as a result of the early postnatal TSH surge (21) . There is evidence that T 3 itself induces DI activity, as was found in experiments in mice (23) and men (26) , and in FTRL-5 cell cultures (27) . We postulated that the thyroidal T 3 surge thus causes an increase in liver and/ or thyroidal DI resulting in an increased rate of T 3 production. Preterm infants have a much lower T 3 surge (21) and also an immature deiodinating system with low DI (21) and/or high DIII activity (28) . Indeed, their plasma T 3 is much lower than in full term infants during the first 4±6 weeks of life (2) . The single T 3 administration shortly after birth imitates the postnatal T 3 surge. Although levels of T 3 are still below the levels in term infants, T 3 is increased compared with historical controls. This can be explained by the induction of conversion of T 4 to T 3 through enhanced DI activity by T 3 itself. The fact that the effect on plasma T 3 occurs both in a situation of TSH suppression, as in the infants ,28 weeks GA under T 4 supplementation, and in a situation of normal TSH levels, as in the infants 28±30 weeks GA, may suggest that extrathyroidal, rather than thyroidal DI is activated by T 3 injection.
There is only little experience with T 3 treatment in premature infants. In a case control study Eggermont et al. treated 10 premature infants with a mean GA of 28.7 weeks with 5 mg/kg/d of T 3 during 6 weeks (29). Scho Ènberger et al. (30) studied the effect of the combined treatment with T 4 (25 mg) and T 3 (5 mg) in 45 premature infants in a quasi-randomized manner. Both studies used much higher doses of T 3 , and administered T 3 on a daily basis during a period of time. Although the methodology of these studies was far from optimal, positive clinical results from the treatment were claimed (30) .
We are aware that, because of the trial design, comparability between the infants of the present study, who were born in 1998, and the historical control group, who were recruited between 1991 and 1993, is not optimal. More recent data from our unit about the spontaneous course of thyroid hormones in premature infants were not available. We have shown (2) that, of both thyroid hormones, T 4 decreases most in infants of lower GA or higher morbidity. Plasma T 3 follows the changes of T 4 to a lesser extent. On the basis of the plasma T 4 levels, which were either similar in both groups (infants 28±30 weeks GA) or lower in the T 3 -treated group as compared with the control group (infants ,28 weeks GA), we conclude that the higher T 3 levels found in the study infants were probably related to the T 3 injection, and not to differences in patient characteristics or treatment policies. The results need to be confirmed in a randomised set up. Possible positive effects on clinical outcome can then be studied.
The present study was designed to investigate the effects of T 3 administration on thyroid hormone levels. Any clinical effect of treatment with T 3 should be evaluated with a randomized controlled clinical trial. We did not see any significant clinical side effects during the study period. Blood pressure and heart rate did not change with the increased plasma T 3 levels. In our former T 4 trial we found that heart rate was increased in the T 4 group, especially in infants ,28 weeks GA. The combined results of our two studies point towards local T 4 to T 3 conversion in cardiomyocytes by type II deiodinase (DII). Indeed, the presence of DII in human cardiac muscle has been described (31).
Conclusion
Our results indicate that a single administration of T 3 to premature infants of less than 30 weeks GA, given shortly after birth, results in a sustained increase of plasma T 3 levels during the first weeks of life. In infants 28±30 weeks GA this occurs without any effect on plasma T 4 and free T 4 . In infants of ,28 weeks GA, a transient decrease of T 4 and free T 4 is present, which could be due to the T 3 administration or to clinical factors. The single T 3 injection is not associated with clinically important negative side effects.
